Medacta Group (MOVE) Stock Overview
Develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MOVE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Medacta Group SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 150.00 |
| 52 Week High | CHF 157.80 |
| 52 Week Low | CHF 103.60 |
| Beta | 1.14 |
| 1 Month Change | 0% |
| 3 Month Change | 2.04% |
| 1 Year Change | 38.38% |
| 3 Year Change | 39.15% |
| 5 Year Change | 77.51% |
| Change since IPO | 56.09% |
Recent News & Updates
Medacta Group (VTX:MOVE) Is Looking To Continue Growing Its Returns On Capital
Nov 08
Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Oct 21Investor Optimism Abounds Medacta Group SA (VTX:MOVE) But Growth Is Lacking
Oct 01Medacta Group's (VTX:MOVE) Solid Profits Have Weak Fundamentals
Sep 13Recent updates
Medacta Group (VTX:MOVE) Is Looking To Continue Growing Its Returns On Capital
Nov 08Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Oct 21Investor Optimism Abounds Medacta Group SA (VTX:MOVE) But Growth Is Lacking
Oct 01Medacta Group's (VTX:MOVE) Solid Profits Have Weak Fundamentals
Sep 13Should You Investigate Medacta Group SA (VTX:MOVE) At CHF150?
Sep 12Estimating The Fair Value Of Medacta Group SA (VTX:MOVE)
Aug 29Medacta Group (VTX:MOVE) Has Some Way To Go To Become A Multi-Bagger
Aug 01Do Medacta Group's (VTX:MOVE) Earnings Warrant Your Attention?
Jun 24What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
May 24Market Participants Recognise Medacta Group SA's (VTX:MOVE) Earnings Pushing Shares 26% Higher
May 10Medacta Group SA's (VTX:MOVE) CEO Compensation Looks Acceptable To Us And Here's Why
May 01Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly
Apr 24Return Trends At Medacta Group (VTX:MOVE) Aren't Appealing
Apr 10Medacta Group SA (VTX:MOVE) Yearly Results: Here's What Analysts Are Forecasting For This Year
Mar 28Medacta Group SA (VTX:MOVE) Looks Just Right With A 25% Price Jump
Feb 13
New Products Like GMK SpheriKA And NextAR Will Strengthen Future Prospects In The Spine Segment
Medacta's innovation in product launches and medical education expansion drives revenue growth, with a strong focus on the Spine segment and ASCs.Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)
Jan 06The Price Is Right For Medacta Group SA (VTX:MOVE)
Nov 22Is Medacta Group (VTX:MOVE) A Risky Investment?
Oct 14Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate
Sep 06What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
Aug 21Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
Aug 06Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable
Jun 20We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
May 01Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet
Apr 17Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Mar 29Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Feb 22Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around
Feb 07Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult
Dec 18Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Dec 04Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Nov 15Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)
Oct 30If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity
Oct 17Is Medacta Group (VTX:MOVE) Using Too Much Debt?
Sep 29Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Aug 11Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Jul 27Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital
Jul 03At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?
Apr 28Is Medacta Group (VTX:MOVE) A Risky Investment?
Apr 08Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Dec 25Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal
Dec 09Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Nov 09Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching
Sep 16The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence
Aug 20Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors
Jul 02Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?
May 28Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
May 12These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well
Mar 31Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Mar 17Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future
Feb 07Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?
Dec 10Medacta Group (VTX:MOVE) Knows How To Allocate Capital
Nov 05Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly
Sep 30Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?
Aug 26Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital
Jul 20Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?
May 19We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt
Apr 05Shareholder Returns
| MOVE | CH Medical Equipment | CH Market | |
|---|---|---|---|
| 7D | -2.3% | -6.8% | -2.2% |
| 1Y | 38.4% | -18.9% | 7.5% |
Return vs Industry: MOVE exceeded the Swiss Medical Equipment industry which returned -18.9% over the past year.
Return vs Market: MOVE exceeded the Swiss Market which returned 7.5% over the past year.
Price Volatility
| MOVE volatility | |
|---|---|
| MOVE Average Weekly Movement | 3.6% |
| Medical Equipment Industry Average Movement | 4.1% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in CH Market | 7.7% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: MOVE has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: MOVE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 2,041 | Francesco Siccardi | www.medacta.com |
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. Medacta Group SA was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.
Medacta Group SA Fundamentals Summary
| MOVE fundamental statistics | |
|---|---|
| Market cap | CHF 3.01b |
| Earnings (TTM) | CHF 88.24m |
| Revenue (TTM) | CHF 600.51m |
Is MOVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOVE income statement (TTM) | |
|---|---|
| Revenue | €646.07m |
| Cost of Revenue | €209.25m |
| Gross Profit | €436.82m |
| Other Expenses | €341.89m |
| Earnings | €94.93m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.76 |
| Gross Margin | 67.61% |
| Net Profit Margin | 14.69% |
| Debt/Equity Ratio | 48.0% |
How did MOVE perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/20 18:36 |
| End of Day Share Price | 2025/11/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medacta Group SA is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samuel England | Berenberg |
| David Adlington | J.P. Morgan |
| Ilya Burgansky | Research Partners AG |